respiratory disease

Gilead/Galapagos alliance hit again as IPF drug is binned

Gilead and Galapagos’ much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage failure in idiopathic pulmonary fibrosis (IPF).  Ziritaxestat (GLPG1690) – a first-in-class autotaxin inhibitor – was the flagship asset in the $5.11 billion partnership signed by the two companies in 2019, and has been advanced into the phase …

Gilead/Galapagos alliance hit again as IPF drug is binned Read More »

Aptar Pharma Acquires the Assets of Respiratory Startup Cohero Health

What You Should Know: – Apstar Pharma acquires the assets of respiratory health company Cohero Health to expands its digital portfolio with a focus on respiratory disease management. – Cohero Health develops digital tools and technologies to improve respiratory care, reduce avoidable costs, and optimize medication utilization. AptarGroup, Inc., a global leader in consumer dispensing, …

Aptar Pharma Acquires the Assets of Respiratory Startup Cohero Health Read More »